Who
Keli Walbert
Director
Company insider
Files Form 4 as: Director, Hemab Therapeutics Holdings; Director, Spruce Biosciences; Director, Apellis Pharmaceuticals.
In numbers
- Trades disclosed
- 23
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 8 Jan 2025
- Last trade
- 24 Sep 2026
- Last filed
- 25 Sep 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Sep 2026filed 25 Sep 2026 | COAG Hemab Therapeutics Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —36,000 at $0.00 | filing |
| 24 Sep 2026filed 25 Sep 2026 | COAG Hemab Therapeutics Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —36,000 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | SPRB Spruce Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,700 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | SPRB Spruce Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,700 at $0.00 | filing |
| 14 May 2026filed 14 May 2026 | Apellis PharmaceuticalsBiotechnology | SEC FORM 4 Code U | —17,051 | filing |
| 14 May 2026filed 14 May 2026 | Apellis PharmaceuticalsBiotechnology | SEC FORM 4 Code D | —8,332 | filing |
| 14 May 2026filed 14 May 2026 | Apellis PharmaceuticalsBiotechnology | SEC FORM 4 Code D | —664 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —14,684 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —15,388 | filing |
| 14 May 2026filed 14 May 2026 | Apellis PharmaceuticalsBiotechnology | SEC FORM 4 Code D | —7,297 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —14,684 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —15,388 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticals | SEC FORM 4 Code U | —17,051 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticals | SEC FORM 4 Code D | —8,332 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticals | SEC FORM 4 Code D | —664 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticals | SEC FORM 4 Code D | —7,297 | filing |
| 1 Jan 2026filed 5 Jan 2026 | Apellis PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —7,961 at $0.00 | filing |
| 1 Jan 2026filed 5 Jan 2026 | Apellis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,684 at $0.00 | filing |
| 1 Jan 2026filed 5 Jan 2026 | Apellis Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —14,684 at $0.00 | filing |
| 1 Jan 2026filed 5 Jan 2026 | Apellis Pharmaceuticals | SEC FORM 4 Code A | —7,961 at $0.00 | filing |
News
Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbertmanilatimes.net · 24 Sep 2026
1 headline in the last 90 days name Keli Walbert; no company of theirs resolves to a name we track.
Sectors
No trade we could place in a sector.